BioSpace News Archive

Abliva AB today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM CET, featuring Amel Karaa, MD (Massachusetts General Hospital), who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial disease.

AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders.

Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.

Outlook Therapeutics, Inc. today announced the submission of its Marketing Authorization Application (MAA) to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) seeking authorization of ONS-5010/LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD).

Chromocell Therapeutics Corporation today announced that its CEO Frank Knuettel, will be presenting at Alliance Global Partners Healthcare Company Showcase on Tuesday, May 21, 2024.

Baylor Genetics today announced the availability of a new RNA sequencing test, RNAseq, for Whole Exome and Whole Genome Sequencing (WES/WGS).

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2024.

Quince Therapeutics, Inc. provided an update on the company’s development pipeline and reported financial results for the first quarter ended March 31, 2024.

Avanos Medical, Inc. announced that Sigfrido Delgado has been appointed senior vice president, integrated supply chain.

Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update.